We are live on
!
Find out more
EP
Eversept Partners Portfolio holdings
AUM
$1.93B
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter
Est. Return
-0.2%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$174M
AUM Growth
–
Cap. Flow
+$152M
Cap. Flow
% of AUM
87.51%
Top 10 Holdings %
Top 10 Hldgs %
61.99%
Holding
46
New
46
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AERI
Aerie Pharmaceuticals
AERI
|
+$14.6M |
| 2 |
ARRY
Array Biopharma Inc
ARRY
|
+$14.1M |
| 3 |
Sanofi
SNY
|
+$8.67M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$8.61M |
| 5 |
TSRO
TESARO, Inc.
TSRO
|
+$8.41M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 75.41% |
| 2 | Miscellaneous | 13.82% |
| 3 | Industrials | 4.17% |
| 4 | Real Estate | 3.32% |
| 5 | Financials | 3.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$825B
| $24M | 13.82% |
+90,000
| New | +$23.4M |
|
|
ARRY
2
DELISTED
Array Biopharma Inc
ARRY
| $15.8M | 9.12% |
+1,237,803
| New | +$14.1M |
|
|
AERI
3
DELISTED
Aerie Pharmaceuticals
AERI
| $14.4M | 8.3% |
+241,480
| New | +$14.6M |
|
|
ZGNX
4
DELISTED
Zogenix, Inc.
ZGNX
| $8.75M | 5.03% |
+218,378
| New | +$8.39M |
|
|
5
Vertex Pharmaceuticals
VRTX
$137B
| $8.71M | 5.01% |
+58,122
| New | +$8.61M |
|
|
6
Sanofi
SNY
$107B
| $8.08M | 4.65% |
+187,972
| New | +$8.67M |
|
7
The Ensign Group
ENSG
$10.1B
| $7.38M | 4.25% |
+354,638
| New | +$7.61M |
|
|
RCM
8
DELISTED
R1 RCM Inc. Common Stock
RCM
| $7.24M | 4.17% |
+1,641,878
| New | +$6.42M |
|
|
TSRO
9
DELISTED
TESARO, Inc.
TSRO
| $7.11M | 4.09% |
+85,740
| New | +$8.41M |
|
|
RDUS
10
DELISTED
Radius Health, Inc.
RDUS
| $6.18M | 3.56% |
+194,501
| New | +$6.1M |
|
|
TLGT
11
DELISTED
Teligent, Inc
TLGT
| $6.03M | 3.47% |
+166,089
| New | +$7.95M |
|
12
eHealth
EHTH
$38.4M
| $5.71M | 3.28% |
+328,555
| New | +$7.35M |
|
13
Puma Biotechnology
PBYI
$468M
| $5.4M | 3.11% |
+54,649
| New | +$6.12M |
|
|
NVRO
14
DELISTED
NEVRO CORP.
NVRO
| $4.48M | 2.58% |
+64,850
| New | +$5.19M |
|
15
BioMarin Pharmaceuticals
BMRN
$12.5B
| $4.08M | 2.34% |
+45,700
| New | +$3.97M |
|
|
ALXN
16
DELISTED
Alexion Pharmaceuticals
ALXN
| $4.01M | 2.31% |
+33,500
| New | +$4.08M |
|
|
QCP
17
DELISTED
Quality Care Properties, Inc.
QCP
| $3.43M | 1.98% |
+248,646
| New | +$3.8M |
|
|
AVXS
18
DELISTED
AveXis, Inc. Common Stock
AVXS
| $3.03M | 1.74% |
+27,370
| New | +$2.75M |
|
|
EVHC
19
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $2.75M | 1.58% |
+79,520
| New | +$2.78M |
|
|
ABLX
20
DELISTED
Ablynx NV
ABLX
| $2.52M | 1.45% |
+100,879
| New | +$2.28M |
|
21
CareTrust REIT
CTRE
$9.22B
| $2.34M | 1.35% |
+138,264
| New | +$2.56M |
|
|
MYOK
22
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $2.1M | 1.21% |
+50,000
| New | +$1.93M |
|
23
argenx
ARGX
$64B
| $1.75M | 1% |
+27,660
| New | +$906K |
|
24
Zimmer Biomet
ZBH
$19.2B
| $1.69M | 0.97% |
+14,420
| New | +$1.63M |
|
|
IVC
25
DELISTED
Invacare Corporation
IVC
| $1.64M | 0.94% |
+97,302
| New | +$1.58M |
|
Similar funds
SWM
RIA
SI
SG
DCP
SI
GIA
MFM
Eversept Partners's Q4 2017 Portfolio in Review
Q4 2017 is the first quarter with a 13F filing on record for Eversept Partners, which disclosed 46 positions worth $174M. Its ten largest holdings account for 62% of the portfolio.
Its largest position is Aerie Pharmaceuticals: 241,480 shares worth $14.4M.
By sector, the portfolio is most concentrated in Healthcare at 75% of assets, followed by Miscellaneous and Industrials.
- Eversept Partners's largest Q4 2017 buy was Aerie Pharmaceuticals: 241,480 shares worth $14.4M.
- Eversept Partners's ten largest holdings make up 62% of its $174M portfolio in Q4 2017.
- Eversept Partners disclosed 46 positions in Q4 2017, its first 13F filing on record.
Based on Eversept Partners's 13F filing for Q4 2017, filed 12 Feb 2018.